Browsing by Author "Schechter, Mauro"
Now showing items 1-20 of 24
-
Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil
Grinsztejn, Beatriz et al. | Date Issued: 2006 -
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study
Gandhi, Monica et al. | Date Issued: 2016 -
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV
Schechter, Mauro et al. | Date Issued: 2004 -
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for hiv pre-exposure prophylaxis
Solomon, Marc M. et al. | Date Issued: 2014 -
Continuous increase of cardiovascular diseases, diabetes, and non-HIV related cancers as causes of death in HIV-infected individuals in Brazil: an analysis of nationwide data
Paula, Adelzon Assis de et al. | Date Issued: 2014 -
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial
Mulligan, Kathleen et al. | Date Issued: 2015 -
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
Katlama, Christine et al. | Date Issued: 2009 -
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the benchmrk studies: final results of two randomised, placebo-controlled trials
Eron, Joseph J. et al. | Date Issued: 2013 -
Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men
Anderson, Peter L. et al. | Date Issued: 2012 -
International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status
Truong, Hong-Ha M. et al. | Date Issued: 2017 -
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
Glidden, David V. et al. | Date Issued: 2018 -
Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo Study)
Nunes, Estevão P. et al. | Date Issued: 2009 -
Nota sobre o uso da cloroquina/hidroxicloroquina para o tratamento da COVID-19
Ramos Filho, Celso Ferreira et al. | Date Issued: 2020Uma das razões para o impressionante impacto da pandemia da COVID-19 na saúde mundial é a inexistência, até o presente momento, de vacinas ou antivirais específicos aprovados para prevenir ou tratar a enfermidade, cuja ... -
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study
Liu, Albert et al. | Date Issued: 2014 -
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
Grant, Robert M. et al. | Date Issued: 2010 -
Raltegravir with optimized background therapy for resistant HIV-1 infection
Steigbigel, Roy T. et al. | Date Issued: 2008 -
Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis
Glidden, David V. et al. | Date Issued: 2017 -
Recovery of Bone Mineral Density Following Dis Tenofovir-Based HIV Pre-Exposure Prophylaxis
Glidden, David V. et al. | Date Issued: 2017 -
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
Cooper, David A. et al. | Date Issued: 2008